Conference Reports for NATAP

Back

EASL 48th Annual Meeting April 24th - 28th 2013 The Netherlands, Amsterdam     Summary from EASL 2013 for Hepatitis C - New HCV DAAs on their way soon: what do the phase III studies tell us? - written by Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany (05/16/13)   EASL: New Oral HCV Drugs at EASL - Report 4A   Gilead Reports Interim Data From Phase 2 LONESTAR Study - (05/03/13)   NS5A BMS052 + nuc GS-7977 100% or 95% SVR for Patients Who Did Not Achieve SVR with Boceprevir/Telaprevir Triple Therapy, Resistance & Gt3 - (05/15/13)   Simtuzumab, an Antifibrotic Monoclonal Antibody Against Lysyl Oxidase-Like 2 (LOXL2) Enzyme, Is Safe and Well Tolerated in Patients With Liver Disease - (05/30/13)   An analysis of response rates by fibrosis stage in patients treated with faldaprevir, BI 207127 and ribavirin in the SOUND-C2 study - (05/19/13)   The relationship between sustained virological response and plasma concentrations of faldaprevir or BI 207127 in HCV GT-1-infected patients in SOUND-C2 - (05/19/13)   ITPA gene variants predict haemolytic ribavirin-induced anaemia in patients treated with the interferon-free regimen of faldaprevir, BI 207127 and ribavirin in SOUND-C2 - (05/19/13)   A MULTICENTER STUDY OF PROTEASE INHIBITOR-TRIPLE THERAPY IN HCV-INFECTED LIVER TRANSPLANT RECIPIENTS: REPORT FROM THE CRUSH-C GROUP - (05/18/13)   Predictors of Mortality among United States Veterans with Hepatitis C Virus Infection: 'almost double mortality rate in HCV+ vs HCV- HCV treatment reduced mortality by 50%' - (05/18/13)   HCV-TARGET: A Longitudinal, Observational Study of North American Patients with Chronic Hepatitis C Treated with Boceprevir or Telaprevir - (05/18/13)   HBV at EASL   HBV at EASL: A complete listing of HBV articles at EASL - (05/15/13)   Clinical Characteristics of Patients Who Developed HCC While Receiving Tenofovir Disoproxil Fumarate (TDF) Up to 336 Weeks of Therapy - (06/11/13)   5-year Entecavir treatment in NUC-naïve, field-practice patients with CHB showed excellent viral suppression and safety profile but no prevention of HCC in cirrhotics - (05/15/13)   Liver Disease in HBV-HIV Coinfection- Significant Fibrosis is Present Despite HBV Suppression and Anti-Retroviral Therapy - (05/15/13)   Virological Response Does Not Lower Liver Disease Progression Among Chronic Hepatitis B Cirrhotic Patients Treated with Long-Term Nucleo(t)ide-Analogue - (05/15/13)   INCIDENCE AND CLINICAL CONSEQUENCES OF REDUCED TUBULAR PHOSPHATE REABSORPTION IN NAIVE CHB PATIENTS TREATED WITH TENOFOVIR: A TWO-YEAR FIELD STUDY - (05/15/13)   HARPE Study: Prevalence of Renal Abnormalities in Chronic Hepatitis B Virus Infection - (05/15/13)   FROM COMBINATION-THERAPY TO MONO-THERAPY IN TREATMENT EXPERIENCED CHB PATIENTS WITH VIRAL RISISTENCE OR PARTIAL RESPONSES: FIRST RESULTS OF AN INTERNATIONAL MULTICENTER COHORT STUDY - (05/15/13)   Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: An international multicenter cohort study - (05/15/13)   Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection - (05/13/13)   Efficacy and Safety of Peginterferon Alfa-2a (40KD) in HBeAg-Positive Chronic Hepatitis B PatientsParticipating in a Response-Guided Therapy Study: An Interim Analysis at Week 72 - (05/09/13)   S-collate cohort 'real-life' study: efficacy and safety of peginterferon alfa-2a (40KD) in 1233 patients with chronic hepatitis B according to Asian and Caucasian race - (05/09/13)   Impact of Entecavir Versus Lamivudine on Hepatic HBV Covalently Closed-Circular DNA and Total Hepatic HBV DNA in Nucleoside-Naïve HBeAg Positive Chronic Hepatitis B Patients - (05/08/13)   Long-term Tenofovir Disoproxil Fumarate (TDF) Therapy and the Risk of Hepatocellular Carcinoma - (05/08/13)   Tenofovir Disoproxil Fumarate in Chronic HBV Patients With Normal ALT Levels and High HBV DNA Levels, also titled: TENOFOVIR DF (TDF) COMPARED TO EMTRICITABINE (FTC)/TDF IN HBeAg-POSITIVE, CHRONIC HEPATITIS B (CHB) VIRUS-INFECTED PATIENTS IN THE IMMUNE TOLERANT (IT) PHASE - (05/08/13)   Comparison of Serum HBsAg Declines During Tenofovir Disoproxil Fumarate (TDF) Treatment in Different Chronic Hepatitis B (CHB) Patient Populations - (05/08/13)   HEPATOCELLULAR CARCINOMA (HCC) RISK IN HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHBE-) WITH OR WITHOUT CIRRHOSIS TREATED WITH ENTECAVIR: RESULTS OF THE NATIONWIDE HEPNET.GREECE COHORT STUDY - (05/08/13)   ALT Flares During Treatment with Peginterferon Lambda-1a or Peginterferon Alfa in Patients With HBeAg-positive Chronic Hepatitis B Infection (CHB) - (05/08/13)   IMPROVED HBsAg LOSS RATE IN CHRONIC HEPATITIS B PATIENTS TREATED WITH PROLONGED PEGINTERFERON α-2A COMBINED WITH NUCLEOS(T)IDE ANALOGUE - (05/08/13)   Tenofovir Disoproxil Fumarate (TDF) Is Safe and Well Tolerated in Chronic Hepatitis B (CHB) Patients With Pre-Existing Mild Renal Impairment - (05/08/13)   48 Weeks of Peginterferon Alfa-2a/Ribavirin Improves SVR24 and Decreases Relapse across HCV Genotype 2/3 Patient Subgroups Not Achieving a Rapid Virological Response: N-CORE Study - (05/11/13)   Other Reports at EASL   Sustained Virologic Response With Daclatasvir Plus Sofosbuvir ± Ribavirin (RBV) in Chronic HCV Genotype (GT) 1-Infected Patients Who Previously Failed Telaprevir (TVR) or Boceprevir (BOC) - (04/27/13)   Hepatitis C Treatment Outcomes and Predictors of Response in Treatment-naive Patients Treated with Peginterferon Alfa/Ribavirin in Real-world Italian Clinics Compared with Other Countries: PROPHESYS Sub-analysis - (05/11/13)   Correlation of IL28B Polymorphism with Degree of Fibrosis: Analysis of Treatment-naïve and Treatment-experienced Caucasian Patients Infected with HCV Genotype 1 in the Gen-C Study - (05/11/13)   High Concordance of SVR4, SVR12, and SVR24 in Patients With HCV Infection Who Have Received Treatment With Sofosbuvir - (05/11/13)   FOLLOW-UP AFTER CESSATION OF THERAPY WITH THE DIRECT ACTING ANTIVIRALS IN CHRONIC HEPATITIS C PATIENTS - WHO IS AT THE RISK OF LATE RELAPSE? - (05/11/13)   IMPACT OF HIGHLY EFFECTIVE ANTIVIRAL THERAPY ON THE BURDEN OF HEPATOCELLULAR CARCINOMA IN HEPATITIS C CIRRHOSIS - (05/11/13)   A Clinical Trial Evaluating Low HCV RNA Viremia in Patients Treated with Triple Therapy Including Telaprevir: Implications for Management Using Different Assays in Clinical Practice - (05/11/13)   BL-8030: A Novel, Potent, Selective, Orally Available Inhibitor of Hepatitis C Virus NS3/4A Protease - (05/11/13)   BioLineRx Enrolls First Patient in Phase I/II Clinical Trial for BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C - press release - (05/11/13)   New HCV Drugs - EASL & Beyond - (05/11/13)   No Clinically Significant Pharmacokinetic Interaction Between Sovaprevir and ACH-3102 in Healthy Volunteers - (05/09/13)   ACH-3102, A Second Generation NS5A Inhibitor, Demonstrates Potent Antiviral Activity in Patients with Genotype 1A HCV Infection Despite the Presence of Baseline NS5A-Resistant Variants - (05/09/13)   FINDINGS FROM CLINICAL VIROLOGY STUDIES ON ACH-3102 ARE CONSISTENT WITH PRECLINICAL OBSERVATIONS ON ITS IMPROVED POTENCY AGAINST GENOTYPE-1A HCV AND RESISTANT VARIANTS - (05/09/13)   No Clinically Significant Pharmacokinetic Interaction Between Sovaprevir and ACH-3102 in Healthy Volunteers - (05/09/13)   Findings from Clinical Virology Studies on Sovaprevir, a Phase 2 HCV NS3 Protease Inhibitor, Indicate a High Pharmacological Barrier to Viral Resistance - (05/09/13)   Viral Kinetics Modeling to Predict cEVR and Aid in Dose Selection Decisions for Phase-2/3 Clinical Trials: ACH3102+ Sovaprevir, ACH2684 - (05/09/13)   ACH-2684 Demonstrates Potent Viral Suppression in Genotype 1 Hepatitis C Patients With and Without Cirrhosis: Safety, Pharmacokinetic, and Viral Kinetic Analysis - (05/09/13)   ACH-2684: HCV NS3 PROTEASE INHIBITOR WITH POTENT ACTIVITY AGAINST MULTIPLE GENOTYPES AND KNOWN RESISTANT VARIANTS - (05/09/13)   Direct and indirect cost burden is higher in HCV infection compared with a matched non-HCV infected cohort in a privately-insured population - (05/07/13)   Patient characteristics and utilization of protease inhibitors in hepatitis C virus (HCV) patients in a large payer database - (05/07/13)   Relationship Between Transaminase Levels and Plasma Pharmacokinetics Following Administration of MK-5172 With Pegylated Interferon Alfa-2b and Ribavirin to HCV Genotype 1 Treatment-Naïve Patients - (05/07/13)   Pharmacokinetics of simeprevir (TMC435) in volunteers with moderate or severe hepatic impairment - (05/07/13)   Sofosbuvir Safety and Tolerability in 778 Patients Treated for Up to 24 Weeks in Four Phase 2 Studies - (05/07/13)   Clinical Impact of Viral Load on the Development of Hepatocellular Carcinoma and Liver-related Mortality in Patients with Chronic Hepatitis C Virus Infection - (05/07/13)   Efficacy of Telaprevir Dosed Twice Daily versus Every 8 Hours by IL28B Genotype: Results from the Phase III OPTIMIZE Study - (05/07/13)   High SVR Rates (SVR4) for 12-Week Total Telaprevir Combination Therapy in IL28B CC Treatment-Naïves and Prior Relapsers With G1 Chronic Hepatitis C: CONCISE Interim Analysis - (05/07/13)   Treatment with Telaprevir-based Therapy after Exposure to Peg-IFN/RBV in the REALIZE Study: Results from the Phase IIIb C219 Rollover Study - (05/07/13)   Treatment with Telaprevir/Peg-IFN/RBV After 14-day Telaprevir Exposure in Phase I Studies: Results from the Phase IIIB C219 Rollover Study - (05/07/13)   Telaprevir - Health-related Quality of Life Among Genotype 1 Treatment Experienced Chronic Hepatitis C Patients: Post-hoc Analyses of Data From the Realize Clinical Trial - (05/06/13)   Sustained Viral Response and Safety of Vaniprevir (MK-7009) in Cirrhotic, Treatment-Experienced Patients with Genotype 1 HCV Infection Who Have Failed Previous Pegylated Interferon and Ribavirin - (05/06/13)   VIROLOGIC RESPONSE RATES ARE SIMILAR IN PREVIOUSLY UNTREATED AND PREVIOUSLY TREATED AND RELAPSED PATIENTS RECEIVING BOCEPREVIR TRIPLE THERAPY: A RETROSPECTIVE ANALYSIS - (05/06/13)   PHARMACOKINETIC INTERACTIONS BETWEEN THE HCV PROTEASE INHIBITOR BOCEPREVIR AND SIROLIMUS IN HEALTHY SUBJECTS - (05/06/13)   Resistance Analysis of Cirrhotic Treatment-Experienced Genotype 1 Patients in a Study of MK-7009 in Combination With Pegylated Interferon/Ribavirin - (05/06/13)   Sustained Viral Response and Safety of Vaniprevir (MK-7009) in Cirrhotic, Treatment-Experienced Patients with Genotype 1 HCV Infection Who Have Failed Previous Pegylated Interferon and Ribavirin - (05/06/13)   EASL: New Oral HCV Drugs at EASL - Report 4A - (05/03/13)   Clinical Impact of Viral Load on the Development of Hepatocellular Carcinoma and Liver-related Mortality in Patients with Chronic Hepatitis C Virus Infection - (05/03/13)   End Of Treatment Response After Protease Inhibitor-based Therapy For Hepatitis C Recurrence After Liver Transplantation: A Multicentric European Experience - (05/03/13)   Adherence with Telaprevir bid versus Every 8 Hour Dosing in Treatment-naïve HCV-infected Patients: Results from the Phase III OPTIMIZE Study - (05/03/13)   Safety and Efficacy of Twice Daily versus Every 8 Hour Telaprevir with Peginterferon/Ribavirin in Patients with Cirrhosis - (05/03/13)   Anemia and its Management in Patients Treated with Telaprevir Twice-daily versus Every 8 Hours in the Phase III OPTIMIZE Study - (05/03/13)   Safety & Efficacy of Boceprevir/PegInterferon/Ribavirin (BOC/P/R) Combination Therapy for Chronic HCV G1 Patients with Compensated Cirrhosis: A Meta-Analysis of Five Phase 3 Clinical Trials - (05/03/13)   EASL NEW Oral HCV Drugs - Report 1 of 3 - (04/30/13)   New HCV Drugs: Report 2 - (04/30/13)   HCV New Drugs - Report 3 (ELECTRON Study phase 2: GS7977+Rbv GT1) - (04/30/13)   Resistance Analyses Using Deep and Population Sequencing After 3 Day Monotherapy With GS-9669, a Novel Non-Nucleoside NS5B Inhibitor in Genotype 1 HCV Patients - (04/30/13)   Exposure-Response Analyses of Asunaprevir in Combination With Daclatasvir ± Peginterferon Alfa/Ribavirin Among Patients With Genotype 1 Chronic HCV Infection: Dose Selection for Phase 3 Clinical Trials - (04/30/13)   Combination Therapy of TMC647055 With Simeprevir (TMC435) in Genotype 1 HCV Patients - (04/30/13)   VAST MAJORITY OF DETECTED NS5A RESISTANT VARIANTS ARE NOT AMPLIFIED IN HCV PATIENTS DURING 3-DAY MONOTHERAPY WITH THE OPTIMIZED NS5A INHIBITOR PPI-668 - (04/29/13)   SAFETY OF TRIPLE THERAPY WITH TELAPREVIR OR BOCEPREVIR IN HEPATITIS C PATIENTS WITH ADVANCED LIVER DISEASE - PREDICTIVE FACTORS FOR SEPSIS - (04/29/13)   Study of ABT-267 2-Day Monotherapy Followed By 12-Week Combination Therapy In Treatment-Naïve Patients With Chronic HCV Genotype 1 Infection - (04/29/13)   VX-135, A POTENT SINGLE DIASTEREOMER OF ALS-2200, FOR THE TREATMENT OF CHRONIC HEPATITIS - (04/29/13)   In Vitro Resistance to ALS-2200, a Potent Nucleotide Polymerase Inhibitor for the Treatment of Chronic Hepatitis - (04/29/13)   No S282T Mutation Detected by Deep Sequencing in a Large Number of HCV Patients Who Received Sofosbuvir With RBV and/or GS-0938: the Quantum Study - (04/29/13)   GS-5816, a Second-Generation HCV NS5A Inhibitor With Potent Antiviral Activity, Broad Genotypic Coverage, and a High Resistance Barrier - (04/29/13)   Healthy Volunteer First-in-Human Evaluation of GS-5816, a Novel Second Generation Broad-Genotypic NS5A Inhibitor With Potential for Once-Daily Dosing - (04/29/13)   Once-Daily Sofosbuvir Plus Ribavirin Given for 12 or 24 Weeks in Treatment-Naïve Patients With HCV Infection: the QUANTUM Study - (04/28/13)   ELECTRON: All-Oral Sofosbuvir-Based 12-Week Regimens for the Treatment of Chronic HCV GT 1 Infection - (04/27/13)   Asunaprevir With Peginterferon-Alfa and Ribavirin in Treatment-Naive Patients With Genotype-1 or -4 Chronic Hepatitis C: SVR24 Results From a Randomized Phase 2b Study (AI447-016) - (04/27/13)   Treatment With Sofosbuvir + Ribavirin for 12 Weeks Achieves SVR12 of 78% in GT 2/3 Interferon-Ineligible, -Intolerant, or -Unwilling Patients: Results of the Phase 3 POSITRON Trial - (04/27/13)   High Sustained Viral Response of MK-5172 with Pegylated Interferon Alfa-2b and Ribavirin in HCV Genotype 1 Treatment-Naive Non-Cirrhotic Patients - (04/27/13)   6-Week Treatment With Ledipasvir (NS5A Inhibitor) Plus GS-9451 (NS3 Inhibitor) With Peg-IFN/RBV in Naïve IL28B CC Subjects With Genotype 1 CHC: High Rates of Sustained Virological Response - (04/27/13)   Antiviral Efficacy of the Once Daily NS3 Protease Inhibitor GS-9451, the Non-Nucleoside NS5B Inhibitor Tegobuvir (GS-9190), and Pegylated Interferon + Ribavirin in Treatment-Naïve Patients With Genotype 1 Hepatitis C Infection - (04/27/13)   Synergistic Interactions of HCV NS5A Replication Complex Inhibitors Sensitize Resistant Variants and Enhance the Efficacy of Daclatasvir (DCV, BMS-790052) In Vitro and In Vivo - (04/27/13)   FALDAPREVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN CHRONIC HCV GENOTYPE-1 TREATMENT-NAIVE PATIENTS - (04/27/13)   DACLATASVIR COMBINED WITH PEGINTERFERON ALFA 2A ALFA-AND RIBAVIRIN FOR 12 OR 16 WEEKS IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 2 OR 3 INFECTION: COMMAND GT 2/3 STUDY - (04/27/13)   Treatment With Sofosbuvir + Peginterferon + Ribavirin for 12 Weeks Achieves 90% SVR12 in Treatment-Naïve Genotype 1, 4, 5, and 6 HCV-Infected Patients: The NEUTRINO Study - (04/27/13)   Simeprevir (TMC435) with peginterferon-α2a or -α2b and ribavirin in treatment-naïve HCV genotype 1 patients: QUEST-2, a randomised Phase III trial - (04/27/13)   ALS-2200, A Novel Once-daily Nucleotide HCV Polymerase Inhibitor, Demonstrated Potent Antiviral Activity In Treatment-naïve Patients with Compensated Cirrhosis or Genotype 2-4 Chronic Hepatitis C - (04/27/13)   SVR12 rates and safety of triple therapy including telaprevir or boceprevir in 485 cirrhotic non responders treated in the French Early Access Program (ANRS CO20-CUPIC) - (04/27/13)   SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/- RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY - (04/25/13)   Phase 3 Randomized Controlled Trial of All-Oral Treatment With Sofosbuvir + Ribavirin for 12 Weeks Compared to 24 Weeks of PEG + Ribavirin in Treatment-Naïve GT 2/3 HCV-Infected Patients (FISSION) - (04/25/13)   All Oral Therapy With Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment-Experienced Genotype 2/3 HCV-Infected Patients: Results of the Phase 3 FUSION Trial - (04/25/13)   Interim Analysis of an Interferon (IFN)- and Ribavirin (RBV)-Free Regimen of Daclatasvir (DCV), Asunaprevir (ASV), and BMS-791325 in Treatment-Naive, Hepatitis C Virus Genotype 1-Infected Patients - (04/25/13)   Evaluation of Pharmacokinetic Drug-Drug Interaction (DDI) Between BMS-791325, an NS5B Non-Nucleoside Polymerase Inhibitor, Daclatasvir and Asunaprevir in Triple Combination in HCV Genotype 1-Infected Patients - (04/25/13)   Simeprevir (TMC435) with peginterferon/ribavirin for chronic hCV genotype 1 infection in treatment-naïve patients: results from QUEST-1, a Phase III trial - (04/25/13)   Vertex Announces New Data that Showed High Viral Cure Rates with a Total of 12 and 24 Weeks of Telaprevir Combination Treatment Among People with Genotype 1 Hepatitis C Who Have the IL28B CC Genotype - press release - (04/24/13)   Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options - (04/24/13)   ALS-2200 (VX-135) Viral Kinetic Study Shows Significant Reduction in HCV RNA in People with Genotype 1 Hepatitis C Virus Infection and Cirrhosis, and in People with Genotypes 2, 3 or 4 HCV Infection - (04/23/13)   Merck to Present Updated Interim Data from Phase II Trial Evaluating Investigational NS3/4A Protease Inhibitor MK-5172 for Chronic Hepatitis C Virus Genotype 1 Infection at the International Liver Congress™ - (04/23/13)   Findings from Two Phase 3 Studies of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients - (04/23/13)   Boehringer Ingelheim announces results from one of its HCV Phase III trials: Investigational compound faldaprevir+ shows high viral cure and early treatment success in treatment-naïve patients with genotype-1 hepatitis C - press release - (04/23/13)   New Data from AbbVie's Phase IIb Aviator Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with HCV Genotype 1 - press release - (04/23/13)   DATA FROM PHASE 3 STUDIES OF GILEAD'S SOFOSBUVIR FOR HEPATITIS C TO BE PRESENTED AT 48TH ANNUAL EASL MEETING; FINDINGS PUBLISHED ONLINE TODAY IN THE NEW ENGLAND JOURNAL OF MEDICINE - Press Release - (04/23/13)   High Rates of SVR Demonstrated in Phase II Study with Investigational Triple DAA Regimen of Daclatasvir, Asunaprevir and BMS-791325 in Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C Infection - press release - (04/23/13)